Recombinant Human CHRNb4 Protein，His

CHRNb4, or the nicotinic acetylcholine receptor subunit beta-4, has garnered significant attention in recent years due to its pivotal role in neurotransmission and its involvement in various neurological disorders. This receptor subunit is a component of heteromeric nicotinic receptors, which are crucial for mediating cholinergic signaling in both the central and peripheral nervous systems. Research has indicated that CHRNb4 plays a critical role in modulating synaptic plasticity, attention, and learning processes, making it a subject of interest in the context of cognitive function and neurodegenerative diseases such as Alzheimer's and Parkinson's. Additionally, polymorphisms in the CHRNb4 gene have been associated with susceptibility to nicotine addiction and other psychiatric conditions. The study of recombinant CHRNb4 protein aims to elucidate its structure, function, and interactions with other receptor subunits, providing insights into its physiological roles and potential as a therapeutic target. As such, the recombinant protein research facilitates the understanding of ion channel dynamics, pharmacological profiles, and the design of novel compounds that can selectively modulate CHRNb4 activity, offering promising avenues for treatment strategies in disorders linked to cholinergic dysfunction. By advancing our grasp of CHRNb4’s mechanistic pathways, researchers hope to unravel the complexities of cholinergic signaling and its implications in health and disease.